2026 Step Therapy Requirements

Effective 10/01/2026

arb step

Products Affected

- *azilsartan medoxomil 40 mg tablet*
- *azilsartan medoxomil 80 mg tablet*
- EDARBI 40 MG TABLET
- EDARBI 80 MG TABLET
- EDARBYCLOR 40 MG-12.5 MG TABLET
- EDARBYCLOR 40 MG-25 MG TABLET

Details

Criteria	Coverage of Edarbi, Edarbyclor, and azilsartan products require a trial of two select generic angiotensin receptor blockers (ARB) or ARB combinations. If the required drugs appear in the prescription profile in the last 365 days, then additional documentation is not required.

bempedoic acid step

Products Affected

- NEXLETOL 180 MG TABLET
- NEXLIZET 180 MG-10 MG TABLET

Details

Criteria	Coverage of Nexletol or Nexlizet requires either (1) a trial of ONE of the following generic statins: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin, or (2) documentation patient cannot tolerate statins. For (1) above, if the required drug appears in the prescription profile in the last 365 days, then additional documentation is not required.

penicillamine step

Products Affected

- *penicillamine 250 mg capsule*
- *trientine 250 mg capsule*
- *trientine 500 mg capsule*

Details

Criteria	Coverage of penicillamine capsules or trientine capsules requires a trial of penicillamine tablets (generic for Depen). If the required drug appears in the prescription profile in the last 365 days, then additional documentation is not required.

sglt2 step

Products Affected

- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	Coverage of Jardiance or Synjardy requires a trial of brand Farxiga, brand Xigduo, generic dapagliflozin, or generic dapagliflozin/metformin. If the drug is being requested to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease, then the prerequisite trial is not required. If the required drugs appear in the prescription profile in the last 365 days, then additional documentation is not required.

INDEX OF DRUGS

azilsartan medoxomil 40 mg tablet 1
azilsartan medoxomil 80 mg tablet 1
EDARBI 40 MG TABLET 1
EDARBI 80 MG TABLET 1
EDARBYCLOR 40 MG-12.5 MG TABLET 1
EDARBYCLOR 40 MG-25 MG TABLET 1
JARDIANCE 10 MG TABLET 4
JARDIANCE 25 MG TABLET 4
NEXLETOL 180 MG TABLET 2
NEXLIZET 180 MG-10 MG TABLET 2
penicillamine 250 mg capsule 3
SYNJARDY 12.5 MG-1,000 MG TABLET 4
SYNJARDY 12.5 MG-500 MG TABLET 4
SYNJARDY 5 MG-1,000 MG TABLET 4
SYNJARDY 5 MG-500 MG TABLET 4
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE 4
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE 4
SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE 4
SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE 4
trientine 250 mg capsule 3
trientine 500 mg capsule 3